These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22445507)

  • 1. [Are drugs worth their cost?].
    Martín-Conde JA; Tévar Alfonso E; García García FJ
    Farm Hosp; 2011 May; 35 Suppl 2():32-9. PubMed ID: 22445507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spending on medicines in Israel in an international context.
    Sax P
    Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Medical experts groups and choice of medications. A fair prioritization process guarantees the reliability of the choice of medications].
    Garpenby P
    Lakartidningen; 2004 Aug; 101(32-33):2480-2, 2484. PubMed ID: 15346621
    [No Abstract]   [Full Text] [Related]  

  • 4. [Assessment of the pharmaceutical expenditure in Hungary].
    Inotai A; Merész G; Kaló Z
    Acta Pharm Hung; 2010; 80(4):162-72. PubMed ID: 21404477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of new drug introduction on drug expenditure in primary health care in Catalunya, Spain.
    Zara C; Torralba M; Sotoca JM; Prat A; Faixedas MT; Gilabert A
    Ann Pharmacother; 2005 Jan; 39(1):177-82. PubMed ID: 15572601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].
    Delwel GO; Sprenger MJ
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1068-71. PubMed ID: 12085554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of new drugs and indications in 2002: financial speculation or better patent care?
    Prescrire Int; 2003 Apr; 12(64):74-7. PubMed ID: 12674131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surviving the blockbuster syndrome.
    Service RF
    Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490
    [No Abstract]   [Full Text] [Related]  

  • 11. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costing drug development.
    Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacoeconomic analyses--chance or 4th hurdle for innovative drugs].
    Krammer H
    Wien Med Wochenschr; 2006 Dec; 156(23-24):606-11. PubMed ID: 17211764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New drugs in Spain -- when are they to be considered cost-effective alternatives and profitable investments for the National Health System? ].
    Soto Alvarez J
    Farm Hosp; 2004; 28(4):299-304. PubMed ID: 15369442
    [No Abstract]   [Full Text] [Related]  

  • 15. The effects of copayments and generic substitution on the use and costs of prescription drugs.
    Smith DG
    Inquiry; 1993; 30(2):189-98. PubMed ID: 8314607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of managerial intervention on drug utilization pattern at King Chulalongkorn Memorial Hospital.
    Limpanasithikul W; Wangsaturaka D; Nantawan P; Itthipanichapong C; Thamaree S; Wittayalertpanya S; Ketcharoen A; Taworn N; Kemsri W; Kusolsomboon T; Tangphao O
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S336-43. PubMed ID: 12188432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent trends in drug prescribing rates and costs in New Zealand.
    Malcolm LA; Mehl A
    N Z Med J; 1988 May; 101(845):233-6. PubMed ID: 3368132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of new and continuing prescription drug use on cost: a longitudinal analysis of chronic and seasonal utilization.
    Fairman KA
    Clin Ther; 2000 May; 22(5):641-52. PubMed ID: 10868561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The use of modern economic methods for the rational choice of drugs].
    Khveshchuk PF; Rudakova AV; Galin AL
    Voen Med Zh; 1999 Aug; 320(8):54-9. PubMed ID: 10524003
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.